10-Q: Relmada Therapeutics Refocuses Pipeline, Secures $94M Funding

Relmada Therapeutics reports a strategic pipeline overhaul, including two program terminations and the acquisition of two new drug candidates, alongside a significant $94 million capital raise to fund operations for the next 12 months.

Summary

• Relmada Therapeutics has undergone a significant strategic review, terminating the Esmethadone (REL-1017) and psilocybin (REL-P11) development programs.
• The company acquired Sepranolone for $3 million and licensed NDV-01 for an upfront payment of $3.5 million plus 3,017,420 shares and potential milestones up to $200 million.
• Net loss for the nine months ended September 30, 2025, decreased to $37.5 million from $61.3 million in the prior year.
• Operating expenses significantly decreased by $26 million for the nine months ended September 30, 2025, primarily due to the winding down of previous studies.
• Successfully raised approximately $94 million in net proceeds from an underwritten offering of common stock and pre-funded warrants on November 5, 2025.
• Regained compliance with Nasdaq's minimum bid price rule on September 15, 2025.
• Nine-month safety and efficacy data for NDV-01 Phase 2 study in high-risk NMIBC showed a 92% complete response rate anytime (23/25 patients) and 85% at 9 months (17/20 patients), with no new safety signals or Grade 3 adverse events.
• FDA alignment was secured for the planned Phase 3 pivotal program for NDV-01, expected to begin in H1 2026, for both BCG-unresponsive and intermediate-risk NMIBC.
• Sepranolone Phase 2a study in Tourette Syndrome demonstrated a 28% reduction in tic severity and improved quality of life.

Sentiment

Score: 7

Explanation: The company has made a decisive strategic shift, terminating underperforming programs and acquiring promising new assets. The successful $94 million capital raise significantly strengthens its financial position, alleviating immediate going concern doubts. Positive early clinical data for NDV-01 and FDA alignment for NDV-01 Phase 3, coupled with promising Sepranolone data, indicate a positive trajectory for the refocused pipeline. While significant accumulated losses persist, the proactive measures and clinical progress suggest an improved outlook.

Positives

• Significant reduction in net loss for the nine months ended September 30, 2025, to $37.5 million from $61.3 million in the prior year period.
• Operating expenses decreased by $26 million for the nine months ended September 30, 2025, reflecting cost management and program refocus.
• Successful completion of an underwritten offering on November 5, 2025, raising approximately $94 million in net proceeds, significantly improving liquidity and alleviating going concern doubts.
• Regained compliance with Nasdaq's minimum bid price requirement on September 15, 2025.
• Positive nine-month safety and efficacy data from the Phase 2 study of NDV-01 in high-risk NMIBC, showing a 92% complete response rate anytime and 85% at 9 months, with a favorable safety profile.
• Secured FDA alignment on key elements of the planned Phase 3 pivotal program for NDV-01, expected to commence in H1 2026.
• Sepranolone Phase 2a study showed promising results in Tourette Syndrome, including a 28% reduction in tic severity and improved quality of life.
• Strong intellectual property portfolios for both Sepranolone (beyond 2030) and NDV-01 (beyond 2038).

Negatives

• Termination of the Esmethadone (REL-1017) program effective July 7, 2025, following a 2024 setback.
• Termination of the psilocybin (REL-P11) development program effective May 12, 2025.
• Continued net losses and negative cash flows from operations since inception, with an accumulated deficit of $678.4 million as of September 30, 2025.
• Cash and cash equivalents decreased significantly to $1.38 million as of September 30, 2025, from $3.86 million at December 31, 2024, prior to the recent capital raise.
• Short-term investments decreased to $12.5 million as of September 30, 2025, from $41.05 million at December 31, 2024.

Risks

• Dependence on collaborative arrangements.
• Development by the company or its competitors of new technological innovations.
• Dependence on key personnel.
• Protection of proprietary technology.
• Compliance with FDA and other governmental regulations and approval requirements.
• Inherent uncertainties in litigation, with no prediction of outcome possible with total confidence.
• The company has incurred losses and negative cash flows from operations since inception and expects to incur additional losses until it can generate significant revenue from product commercialization.
• No assurance that research and development will be successfully completed or that any product will be approved or commercially viable.
• New risks may emerge, and the company cannot predict all risk factors or their impact on business.

Future Outlook

Relmada Therapeutics expects to initiate Phase III programs for NDV-01 in high-risk, 2nd line BCG-unresponsive NMIBC and intermediate risk NMIBC in the adjuvant setting in the first half of 2026. Additionally, a Phase IIb study for Sepranolone in Prader-Willi Syndrome is anticipated to begin in the first half of 2026. The company also expects twelve-month data from the ongoing Phase 2 NMIBC study for NDV-01 in early 2026 and United States Investigative New Drug clearance for NDV-01 in the first half of 2026.

Management Comments

• Management believes that the Company's existing cash and cash equivalents and short-term investments will enable it to fund operating expenses and capital expenditure requirements for at least 12 months from the issuance of these unaudited condensed consolidated quarterly financial statements.
• Management's plans alleviated substantial doubt about the Company's ability to continue as a going concern as of September 30, 2025.
• We substantially redesigned our development programs following a comprehensive strategic review in late 2024 and early 2025.
• The most promising path to create shareholder value was to lever our extensive drug development expertise and clinical operations capabilities by acquiring new development candidates, while pausing further work on esmethadone (d-methadone, dextromethadone or REL-1017).
• We intend to develop NDV-01 for the treatment of high-risk, 2nd line BCG-unresponsive NMIBC and also in intermediate risk patients in the adjuvant setting.
• We expect to initiate a Phase IIb study in Prader-Willi Syndrome in the first-half of 2026.

Industry Context

Relmada's strategic pivot, terminating two programs (Esmethadone and psilocybin) and acquiring two new candidates (NDV-01 and Sepranolone), reflects a common trend in the biotechnology industry where companies frequently re-evaluate their pipelines based on clinical trial outcomes and market potential. The focus on NMIBC with NDV-01 is particularly relevant given the global BCG shortage, positioning the company to address a significant unmet need with a potentially more convenient and effective treatment. The development of Sepranolone for rare neurological disorders like Prader-Willi Syndrome and Tourette Syndrome aligns with the industry's increasing interest in orphan drug designations and specialized treatments.

Comparison to Industry Standards

• NDV-01's combination therapy of gemcitabine and docetaxel has shown response rates and Recurrence-Free Survival comparable to or better than BCG, which is a standard treatment for NMIBC.
• The conventional administration of gemcitabine and docetaxel is cumbersome, requiring sequential drug delivery over three to four hours, while NDV-01 aims for a single administration in less than 10 minutes, offering improved patient convenience and extended tumor exposure.
• Sepranolone's Phase 2a results in Tourette Syndrome, showing a 28% reduction in tic severity (YGTSS) and improved quality of life, are competitive within the landscape of treatments for neurological disorders, especially given the absence of CNS off-target effects.

Legal Proceedings

• The company is currently not aware of any legal proceedings or potential claims against it whose outcome would be likely, individually or in the aggregate, to have a material adverse effect on the company's business, financial condition, operating results, or cash flows.

Stakeholder Impact

• Shareholders: Dilution from the recent $94 million capital raise, but improved financial stability and a refocused pipeline with promising clinical assets could lead to long-term value creation. Regaining Nasdaq compliance removes a delisting risk.
• Employees: Continued employment and potential growth opportunities within the refocused R&D programs. Stock-based compensation remains a significant component of overall compensation.
• Customers (future patients): Potential for new treatment options for non-muscle invasive bladder cancer (NDV-01) and neurological disorders like Prader-Willi Syndrome and Tourette Syndrome (Sepranolone).
• Creditors: Improved liquidity from the capital raise reduces immediate solvency concerns.
• Suppliers/Partners: New licensing agreements with Asarina Pharma AB and Trigone indicate active collaboration and potential for future partnerships.

Next Steps

• NDV-01 Twelve-month data from ongoing Phase 2 NMIBC Study in early 2026.
• NDV-01 United States Investigative New Drug clearance in 1st Half 2026.
• Initiation of NDV-01 High-risk, 2nd line BCG-unresponsive NMIBC Phase III Trial in 1st Half 2026.
• Initiation of NDV-01 Intermediate Risk in the Adjuvant Setting Phase III Trial in 1st Half 2026.
• Initiation of Sepranolone clinical trial in Prader-Willi Syndrome in 1st Half 2026.
• Management will evaluate the size and scope of any subsequent trials that will affect the timing of additional financings beyond the next 12 months.

Key Dates

Recommendation

Relmada Therapeutics has undergone a significant strategic overhaul, terminating two programs and acquiring two new, promising drug candidates. The successful $94 million capital raise has addressed immediate liquidity concerns and alleviated substantial doubt about the company's going concern status for the next 12 months. Positive Phase 2 data for NDV-01 and FDA alignment for Phase 3 trials, along with encouraging Phase 2a data for Sepranolone, provide a clearer path forward. However, the company still faces substantial accumulated deficits and will require further financing for subsequent clinical trials. The stock has likely seen a positive reaction to the capital raise and clinical updates, but the long-term success of the new pipeline is still subject to significant clinical and regulatory risks. A 'hold' recommendation is appropriate to observe the execution of the Phase 3 trials and further clinical development of Sepranolone before a stronger stance can be taken.

Keywords

Biotechnology, Clinical-stage, NDV-01, Sepranolone, NMIBC, Prader-Willi Syndrome, Tourette Syndrome, Bladder Cancer, Neurosteroid, Drug Development, SEC Filing, RLMD, Nasdaq Compliance, Capital Raise, Phase 2 Clinical Trial, Phase 3 Clinical Trial, FDA Alignment